# MEIS2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MEIS2 is a TALE-class homeodomain transcription factor crucial for craniofacial morphogenesis, cardiogenesis, neurogenesis, and hematopoiesis, operating through sequence-specific DNA binding and heterodimerization with PBX proteins.
- Heterozygous loss-of-function variants in MEIS2 cause an autosomal dominant syndrome characterized by cleft palate, congenital heart defects, and intellectual disability, with recurrent missense and nonsense mutations identified in the homeodomain.
- MEIS2 acts as a direct pharmacodynamic target of immunomodulatory drugs (IMiDs) like lenalidomide, which enhance its ubiquitination and proteasomal degradation via the CRL4-CRBN E3 ligase complex, contributing to anti-myeloma activity.
- MEIS2 exhibits context-dependent roles in cancer: it functions as an oncogene in neuroblastoma and certain leukemias, promoting cell survival and proliferation, but acts as a tumor suppressor in prostate, gastric, and colorectal cancers, where its silencing is linked to progression and chemoresistance.
- MEIS2 is regulated by retinoic acid signaling, with RA inducing its expression and MEIS2 cooperating with RAR/RXR to amplify RA signals, a feedback loop critical for neural tube patterning and tissue differentiation.
- Alternative splicing generates MEIS2 isoforms (e.g., MEIS2C, MEIS2D) with distinct oncogenic activities, notably promoting hepatocellular carcinoma progression by activating Wnt/β-catenin and Hippo/YAP signaling pathways.

---

## Executive Summary & Key Metadata

| Attribute | Value |
|---|---|
| **HGNC Symbol** | MEIS2 |
| **UniProt Accession** | O14770 |
| **Representative PDB ID** | true (multiple structures available for TALE homeodomain family; direct MEIS2 structures deposited for the homeodomain–DNA complex) |
| **Chromosomal Locus** | 15q14 (GRCh38: chr15:89,033,000–89,240,000; approximate) |
| **Primary Molecular Function** | TALE-class homeodomain transcription factor; sequence-specific DNA binding; transcriptional activator/repressor; developmental master regulator |
| **Disease & Pathology Associations** | MEIS2 haploinsufficiency syndrome (cleft palate, congenital heart defects, intellectual disability); autism spectrum disorder; neuroblastoma; acute myeloid leukemia; multiple myeloma; prostate, gastric, and colorectal cancer; uterine sarcoma (MEIS2::FOXO4 fusion) |

MEIS2 (Meis homeobox 2) encodes a member of the three-amino acid loop extension (TALE) superclass of homeodomain transcription factors. Originally identified through retroviral insertion mutagenesis screens in myeloid leukemias and through homology to *Drosophila* homothorax, MEIS2 has emerged as a central node in developmental gene regulatory networks controlling craniofacial morphogenesis, cardiogenesis, neurogenesis, hematopoiesis, and limb patterning. The gene product operates as a DNA-binding transcription factor that frequently heterodimerizes with PBX proteins and cooperates with HOX factors to execute spatiotemporally precise transcriptional programs. Germline loss-of-function variants produce a recognizable syndromic phenotype, while somatic dysregulation contributes to multiple malignancies. This reference manual provides an exhaustive analysis of MEIS2 genomic architecture, protein structure, signaling networks, pathogenic variation, and therapeutic relevance.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Cytogenetic Context

The human *MEIS2* gene maps to chromosome 15q14, a region recurrently deleted in patients with intellectual disability, palatal anomalies, and congenital cardiac defects. The locus spans approximately 207 kilobases of genomic DNA on the minus strand (GRCh38/hg38: chr15:89,033,000–89,240,000). The gene was first mapped to 15q14 by Smith et al. (1997) using fluorescence *in situ* hybridization and somatic cell hybrid panels. The 15q14 region is gene-dense and contains several other developmentally relevant transcripts, including *TYRO3*, *AQP9*, and *MGA*; however, the MEIS2 phenotype is specifically attributable to MEIS2 dosage reduction, as demonstrated by genotype–phenotype correlation studies in patients with nested deletions.

### 1.2 Promoter Architecture and Regulatory Elements

The MEIS2 promoter region lacks a canonical TATA box but contains multiple CpG islands, consistent with its broad developmental expression and epigenetic regulation. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) studies in embryonic stem cells and neural progenitors have identified binding sites for core pluripotency factors (OCT4, SOX2, NANOG) in the proximal promoter, although MEIS2 expression is largely established after gastrulation.

A defining feature of the MEIS2 locus is the presence of highly conserved noncoding elements (CNEs) that function as tissue-specific enhancers. Freundlich (2016) identified a CNE designated *M2de2* that drives reporter expression in the developing forebrain and pharyngeal arches in zebrafish. Additional CNEs—*M2de1* and *M2de3*—have been characterized as enhancers with distinct spatiotemporal activities. Barrett (2013) demonstrated that a CNE upstream of the zebrafish *meis2.2* isoform directs expression to the hindbrain and cranial ganglia. These CNEs are bound by retinoic acid receptors (RARs), PBX proteins, and MEIS proteins themselves, establishing autoregulatory and feed-forward loops that stabilize expression domains.

Kondo et al. (2014) provided mechanistic insight into enhancer–promoter communication at the Meis2 locus in the mouse midbrain. They showed that Polycomb repressive complex 1 (PRC1) components—specifically variant PRC1 containing PCGF1—mediate long-range chromatin looping between the Meis2 promoter and a tissue-specific enhancer, thereby potentiating transcriptional activation. This finding established that Polycomb proteins can function as architectural facilitators of enhancer–promoter interactions, not merely as transcriptional silencers. The same group later demonstrated that variant PRC1 competes with retinoic acid signaling to repress Meis2 in the distal forelimb bud, providing a boundary mechanism for proximal–distal limb patterning.

### 1.3 Transcription Factor Binding and Epigenetic Regulation

The MEIS2 locus is subject to multilayered transcriptional control. Retinoic acid (RA) is a major upstream inducer: treatment of P19 embryonal carcinoma cells with RA rapidly upregulates Meis2 expression, positioning MEIS2 as an immediate-early RA-responsive gene. The RA response is mediated by RAR/RXR heterodimers binding to retinoic acid response elements (RAREs) within the proximal promoter and the *M2de* enhancers. In the hindbrain, RA-dependent Meis2 expression is required for proper rhombomere identity and segmental organization.

NF-Y, a trimeric CCAAT-box-binding transcription factor, has been shown to bind transposable element-derived regulatory sequences near the MEIS2 locus, potentially contributing to its cell-type-specific expression. Additionally, the pioneer factor NeuroD1 can remodel chromatin at the Meis2 locus during neuronal reprogramming, suggesting that MEIS2 is a downstream target of proneural pioneer factors.

### 1.4 Alternative Splicing and Isoform Diversity

The human MEIS2 gene produces multiple transcript variants through alternative promoter usage and alternative splicing. The major isoforms are:

- **MEIS2A (long isoform)**: Contains all 13 exons; encodes a protein of approximately 55 kDa with full-length N-terminal MEINOX domain and C-terminal homeodomain.
- **MEIS2B**: Uses an alternative 3' exon, producing a shorter C-terminus with altered transactivation properties.
- **MEIS2C and MEIS2D**: Generated by alternative splicing of internal exons; these isoforms lack portions of the MEINOX domain and exhibit differential DNA-binding specificity.
- **MEIS2.2 (zebrafish)**: An N-terminally extended isoform generated by an alternative first exon, regulated by the *M2de1* CNE.

In hepatocellular carcinoma, MEIS2C and MEIS2D isoforms are specifically upregulated and promote tumor progression through Wnt/β-catenin and Hippo/YAP signaling. This isoform-specific oncogenic activity underscores the functional diversification achieved through alternative splicing.

The splice site variant c.438+1G>T, identified in a congenital heart disease patient, disrupts canonical splicing and leads to exon skipping, frameshift, and premature termination. Minigene splicing assays confirmed the pathogenic effect, demonstrating the utility of functional splicing analysis in variant interpretation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human MEIS2 protein (UniProt O14770) comprises 475 amino acids in its canonical isoform. The domain architecture, from N-terminus to C-terminus, is as follows:

1. **MEINOX domain** (residues ~1–200): A bipartite protein–protein interaction module composed of two subdomains, PBC-A (residues ~1–90) and PBC-B (residues ~100–200). The MEINOX domain mediates heterodimerization with PBX proteins and homodimerization with other MEIS family members. It is named after MEIS, PBX, and KNotted (plant homeodomain proteins) that share this domain.

2. **Homeodomain** (residues ~230–290): A canonical 60-amino-acid helix-turn-helix DNA-binding motif. The MEIS2 homeodomain belongs to the TALE class, characterized by a three-amino-acid insertion (proline-tyrosine-proline, or PYP) between helix 1 and helix 2. This insertion alters the recognition helix geometry and confers distinct DNA-binding specificity compared to typical homeodomains.

3. **C-terminal transactivation domain** (residues ~300–475): Contains nuclear localization signals and interaction surfaces for transcriptional coactivators and corepressors. This region is subject to alternative splicing, generating isoforms with differential transactivation capacity.

### 2.2 Structural Biology of the TALE Homeodomain

The TALE homeodomain of MEIS2 recognizes a consensus DNA sequence of TGACAG, with the core TGAC motif being critical for high-affinity binding. The three-amino-acid loop extension (PYP) inserts between helices 1 and 2, causing a rotation of the recognition helix that allows contacts with the major groove in a manner distinct from canonical homeodomains.

Crystal structures of MEIS homeodomains bound to DNA (available for MEIS1 and by homology for MEIS2) reveal that residue Isoleucine 47 (I47) in the recognition helix makes hydrophobic contacts with the thymine methyl group at position 2 of the consensus sequence. The invariant asparagine at position 51 (N51) forms bidentate hydrogen bonds with an adenine at position 3. The PYP insertion positions arginine at residue 55 to contact the phosphate backbone, stabilizing the protein–DNA interface.

### 2.3 MEINOX Domain and PBX Heterodimerization

The MEINOX domain is the defining structural feature of TALE proteins. Structural studies of MEIS1–PBX1 heterodimers (which are directly applicable to MEIS2) show that the PBC-A and PBC-B subdomains form a compact globular structure with a hydrophobic groove that accommodates the N-terminal arm of PBX proteins. The interaction is highly conserved: the MEIS2 MEINOX domain binds PBX1, PBX2, PBX3, and PBX4 with nanomolar affinity.

The MEIS2–PBX heterodimer exhibits cooperative DNA binding. PBX proteins recognize the sequence TGAT, while MEIS2 recognizes TGACAG. When heterodimerized, the complex binds composite sites with the consensus TGATNNATNACAG, allowing combinatorial regulation of downstream targets. This cooperativity is essential for the developmental functions of MEIS2, as PBX–MEIS heterodimers regulate HOX target genes during limb, hindbrain, and cardiac development.

### 2.4 Post-Translational Modifications and Structural Dynamics

MEIS2 is subject to multiple post-translational modifications that modulate its activity:

- **Phosphorylation**: Casein kinase II (CK2) phosphorylates serine residues in the C-terminal domain, enhancing transcriptional activity. Phosphorylation at S336 and S340 has been reported to regulate nuclear retention.
- **Ubiquitination**: MEIS2 is a substrate of the CRL4-Cereblon (CRBN) E3 ubiquitin ligase complex. Immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide enhance CRBN-mediated ubiquitination of MEIS2, leading to proteasomal degradation. This mechanism underlies the anti-myeloma activity of IMiDs and establishes MEIS2 as a direct pharmacodynamic target.
- **Sumoylation**: MEIS2 can be modified by SUMO1 at lysine residues in the MEINOX domain, which reduces its transcriptional activation capacity by promoting recruitment of corepressor complexes.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load MEIS2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14770)

The interactive visualizer provides a fully rotatable, zoomable 3D representation of the MEIS2 protein structure. Users can toggle between cartoon, surface, and electrostatic potential renderings; highlight the MEINOX domain (residues 1–200), homeodomain (residues 230–290), and transactivation domain (residues 300–475); and overlay predicted post-translational modification sites. The visualizer also supports superposition of MEIS2 with MEIS1 and PBX1 structures to examine dimerization interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Networks

MEIS2 functions as a sequence-specific DNA-binding transcription factor that can activate or repress target gene expression depending on cellular context and interacting partners. Genome-wide ChIP-seq studies in neuroblastoma cells identified thousands of MEIS2 binding sites, with enrichment at promoter-proximal regions and enhancers. The consensus binding motif TGACAG is enriched at MEIS2-occupied sites, and motif analysis reveals co-occurrence with PBX and HOX motifs, confirming cooperative DNA binding.

MEIS2 regulates cell cycle progression by directly controlling the expression of M-phase genes. In neuroblastoma cells, MEIS2 depletion causes G2/M arrest and apoptosis, with downregulation of key mitotic regulators including *CCNB1*, *CCNB2*, *CDC25C*, and *AURKA*. Chromatin immunoprecipitation confirmed direct MEIS2 occupancy at the promoters of these genes, establishing MEIS2 as a transcriptional activator of the mitotic program.

### 3.2 Retinoic Acid Signaling

MEIS2 is both a downstream target and a functional partner of retinoic acid signaling. RA induces Meis2 expression in P19 cells and in the developing hindbrain. In turn, MEIS2 cooperates with RAR/RXR to activate RA-responsive genes, creating a positive feedback loop that amplifies RA signals. This autoregulatory loop is critical for anteroposterior patterning of the neural tube and for the differentiation of RA-responsive tissues.

In the developing forebrain, MEIS2 and retinoic acid jointly regulate the arealization of the prefrontal and motor cortices. A retinoic acid autoregulatory loop involving MEIS2 controls the expression of *CYP26B1* (an RA-degrading enzyme) and *RDH10* (an RA-synthesizing enzyme), establishing a morphogen gradient that patterns cortical areas.

### 3.3 WNT/β-Catenin and Hippo/YAP Pathways

In hepatocellular carcinoma, the MEIS2C and MEIS2D isoforms promote tumor progression by activating Wnt/β-catenin signaling. Mechanistically, MEIS2C/D bind to β-catenin and enhance its nuclear translocation, leading to increased transcription of Wnt target genes such as *MYC* and *CCND1*. Additionally, MEIS2C/D interact with YAP1, the effector of the Hippo pathway, and promote its nuclear accumulation, driving expression of Hippo target genes including *CTGF* and *CYR61*. This dual activation of oncogenic signaling pathways positions MEIS2 as a central node in HCC pathogenesis.

### 3.4 Notch Signaling in Cardiac Valve Development

MEIS2 represses the osteoblastic transdifferentiation of aortic valve interstitial cells (VICs) through the Notch1/Twist1 pathway. In calcific aortic valve disease (CAVD), VICs undergo osteogenic differentiation, leading to valve calcification. MEIS2 expression is downregulated during this process, and overexpression of MEIS2 prevents osteoblastic transdifferentiation by activating Notch1 signaling, which in turn suppresses Twist1 expression. This protective role of MEIS2 in valve homeostasis has therapeutic implications for CAVD.

### 3.5 Hematopoietic and Leukemic Signaling

MEIS2 is essential for endothelial-to-hematopoietic transition (EHT) during human embryonic stem cell differentiation. MEIS2 directly targets *TAL1*, a master regulator of hematopoiesis, and its knockdown impairs the generation of hematopoietic progenitors. This function is conserved with MEIS1, which is required for definitive hematopoiesis.

In leukemia, MEIS2 collaborates with oncogenic fusion proteins to drive leukemogenesis. AML1-ETO, the fusion protein generated by the t(8;21) translocation, cooperates with MEIS1 and MEIS2 to induce acute myeloid leukemia in mouse models. Similarly, MN1-induced leukemia requires MEIS2 as a critical downstream effector. MEIS2 is also overexpressed in acute lymphoblastic leukemia, where it contributes to the transformed phenotype.

### 3.6 Protein-Protein Interaction Network

The MEIS2 interactome includes:

- **PBX1-4**: Heterodimerization partners that enhance DNA-binding specificity and transcriptional activity.
- **HOXA/B/C/D proteins**: Cooperative DNA binding at composite HOX-PBX-MEIS sites.
- **PDX1**: In pancreatic acinar cells, MEIS2 (MRG1) forms a trimeric complex with PBX1b and PDX1, converting PDX1 from an endocrine to an exocrine regulator.
- **KLF4**: Cooperative transcriptional activation of target genes in embryonic stem cells.
- **TGIF**: Competitive binding to overlapping DNA sites, providing a mechanism for transcriptional antagonism.
- **CRBN**: Substrate of the CRL4-CRBN E3 ligase, targeted for ubiquitination and degradation.
- **PRC1 components**: Interaction with variant PRC1 complexes for enhancer-promoter looping.
- **FOXO4**: In-frame fusion in uterine sarcoma, generating a MEIS2::FOXO4 chimeric oncoprotein.

### 3.7 Non-Coding RNA Regulation

MEIS2 is regulated by multiple microRNAs:

- **miR-204**: Directly targets the MEIS2 3'UTR and is required for lens and retinal development. Loss of miR-204 leads to MEIS2 overexpression and ocular defects. In trabecular meshwork cells, the FOXC1-miR-204-MEIS2-ITGβ1 regulatory axis controls cell adhesion and cytoskeletal organization.
- **miR-204-5p**: Modulates MEIS2 expression in limbal epithelial cells, affecting retinoic acid signaling and cell maintenance.
- **miR-9**: Indirectly regulates MEIS2 through targeting of cofactors in neural development.

Additionally, MEIS2 mRNA is subject to N6-methyladenosine (m6A) modification. IGF2BP2, an m6A reader, stabilizes MEIS2 mRNA and promotes its translation in ovarian endometriosis, contributing to disease progression.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 MEIS2 Haploinsufficiency Syndrome

Heterozygous loss-of-function variants in MEIS2 cause an autosomal dominant syndrome characterized by the triad of palatal defects, congenital heart defects, and intellectual disability. The syndrome was first delineated through the identification of patients with 15q14 microdeletions, and subsequent studies identified point mutations in the coding region.

The clinical spectrum includes:

- **Palatal anomalies**: Cleft palate, bifid uvula, submucous cleft.
- **Congenital heart defects**: Atrial septal defect (most common), ventricular septal defect, patent ductus arteriosus, tetralogy of Fallot.
- **Intellectual disability**: Ranging from mild to severe; speech delay is prominent.
- **Craniofacial dysmorphism**: Broad forehead, hypertelorism, downslanting palpebral fissures, depressed nasal bridge, micrognathia.
- **Behavioral abnormalities**: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder.
- **Other features**: Seizures, hearing loss, dental anomalies, feeding difficulties.

### 4.2 Pathogenic Variant Spectrum

Verheije et al. (2018) compiled the largest cohort of MEIS2 point mutation cases, identifying 21 individuals with heterozygous loss-of-function variants. The mutational spectrum includes:

- **Nonsense mutations**: p.Arg235Ter, p.Gln245Ter, p.Arg279Ter—all located in or near the homeodomain, resulting in truncated proteins lacking DNA-binding capacity.
- **Frameshift mutations**: Insertions/deletions causing premature termination, predominantly in exons 8-10.
- **Missense mutations**: Concentrated in the homeodomain, affecting DNA-binding residues. Recurrent missense variants include p.Arg235Gly, p.Asn251Ser, and p.Arg279Cys.
- **Splice site mutations**: c.438+1G>T disrupts the donor splice site of exon 4, leading to exon skipping and frameshift.

Douglas et al. (2018) reported de novo missense variants in MEIS2 that recapitulate the microdeletion phenotype, confirming that single-nucleotide variants are sufficient to cause the full syndrome. The missense variants cluster in the homeodomain, with p.Arg235Gly and p.Asn251Ser being recurrent.

### 4.3 Genotype-Phenotype Correlations

Patients with whole-gene deletions generally have more severe phenotypes than those with point mutations, suggesting a contiguous gene syndrome component or a dosage effect. However, Zhang et al. (2021) described siblings with 3' MEIS2 deletions and mild phenotypes (bifid uvula, subtle dysmorphism, normal intelligence), with mosaicism in an unaffected parent. This observation indicates that the phenotypic spectrum is broader than initially appreciated and that low-level parental mosaicism can confound recurrence risk counseling.

Su et al. (2020) documented a child with intellectual disability and cardiac defects carrying a MEIS2 sequence variant inherited from a parent with low-level mosaicism. This case highlights the importance of sensitive variant detection methods in parental testing.

### 4.4 Structural Variants and Chromosomal Rearrangements

Tan et al. (2025) used long-read Nanopore sequencing to identify precise breakpoints of a de novo paracentric inversion disrupting MEIS2 in a Chinese girl with syndromic developmental delay. The inversion breakpoints were localized to intron 2 and the 3' flanking region, resulting in MEIS2 haploinsufficiency. This study demonstrated the utility of long-read sequencing for resolving complex structural variants that are missed by conventional cytogenetics.

### 4.5 MEIS2 in Neurodevelopmental Disorders

MEIS2 has been implicated in autism spectrum disorder (ASD). Roussel et al. (2022) showed that Meis2 mutant mice exhibit impaired cardiac baroreflex regulation, a phenotype associated with autonomic dysfunction in ASD. The study revealed that Meis2 is necessary for the development of primary mechanosensitive neurons involved in touch sensation, linking MEIS2 dysfunction to sensory processing abnormalities in ASD.

Hildebrand et al. (2020) identified MEIS2 variants in patients with severe childhood speech disorder, expanding the phenotypic spectrum to include apraxia of speech. The speech disorder is characterized by impaired planning and coordination of speech movements, consistent with MEIS2 expression in the basal ganglia and cerebellum.

### 4.6 MEIS2 in Cancer

#### 4.6.1 Neuroblastoma

MEIS2 is highly expressed in neuroblastoma cell lines and primary tumors, and is required for tumor cell survival and proliferation. Depletion of MEIS2 causes G2/M arrest and apoptosis, with downregulation of M-phase genes. Time-resolved transcriptome analysis of TH-MYCN-driven murine neuroblastoma identified MEIS2 as an early initiating factor and a core gene regulatory circuitry constituent. MEIS2 is an adrenergic core regulatory transcription factor, and its expression is required for the maintenance of the adrenergic cell identity that characterizes high-risk neuroblastoma.

Gene expression profiling and protein-protein interaction network analysis in MEIS2-depleted neuroblastoma cells revealed alterations in cell cycle, DNA replication, and p53 signaling pathways. These findings support MEIS2 as a therapeutic target in neuroblastoma.

#### 4.6.2 Multiple Myeloma

MEIS2 is a substrate of the CRL4-CRBN E3 ubiquitin ligase, and immunomodulatory drugs (IMiDs) such as lenalidomide enhance its ubiquitination and degradation. MEIS2 expression is required for multiple myeloma cell survival, and its degradation contributes to the anti-myeloma activity of IMiDs. Bromodomain and extra-terminal (BET) protein inhibitors modulate MEIS2 expression and enhance IMiD activity, suggesting combination strategies.

#### 4.6.3 Prostate Cancer

MEIS2 expression is downregulated in prostate cancer progression, particularly in metastatic disease. MEIS1 and MEIS2 are binding partners of HOXB13, and germline mutations in the MEIS-interaction domain of HOXB13 are associated with prostate cancer risk. Epigenetic silencing of MEIS2 through promoter hypermethylation is associated with biochemical recurrence. These findings position MEIS2 as a tumor suppressor in prostate cancer, in contrast to its oncogenic role in neuroblastoma and leukemia.

#### 4.6.4 Gastric and Colorectal Cancer

DNA methylation-mediated downregulation of MEIS2 correlates with tumor development and progression in gastric cancer. Similarly, hypermethylated and downregulated MEIS2 is involved in stemness properties and oxaliplatin-based chemotherapy resistance in colorectal cancer. MEIS2 functions as a tumor suppressor in gastrointestinal malignancies, and its silencing promotes cancer stem cell phenotypes and chemoresistance.

#### 4.6.5 Hepatocellular Carcinoma

In contrast to gastrointestinal cancers, MEIS2C and MEIS2D isoforms are upregulated in hepatocellular carcinoma and promote tumor progression through Wnt/β-catenin and Hippo/YAP signaling. This isoform-specific oncogenic activity highlights the context-dependent functions of MEIS2.

#### 4.6.6 Uterine Sarcoma

Turashvili et al. (2025) reported the first case of high-grade uterine sarcoma with a MEIS2::FOXO4 fusion. The fusion gene retains the MEIS2 N-terminal MEINOX domain and the FOXO4 C-terminal forkhead DNA-binding domain, generating a chimeric transcription factor with aberrant activity. This finding expands the spectrum of MEIS2 fusions in cancer.

#### 4.6.7 Lung Cancer

MEIS2 gene silencing in A549 lung adenocarcinoma cells induces apoptosis and cell cycle arrest, suggesting a pro-survival role in lung cancer. The mechanism involves downregulation of anti-apoptotic genes and upregulation of pro-apoptotic genes.

### 4.7 MEIS2 in Other Diseases

#### 4.7.1 Congenital Heart Disease

MEIS2 is essential for cardiac development, particularly for the formation of the outflow tract and atrioventricular septum. Meis2 is required for cranial and cardiac neural crest development, and its loss leads to cardiac malformations. The splice site variant c.438+1G>T was identified in a congenital heart disease patient with intellectual disability.

#### 4.7.2 Inner Ear Development

Meis2 is required for inner ear formation and proper morphogenesis of the cochlea. Meis2 knockout mice exhibit severe inner ear defects, including failure of otic vesicle formation and cochlear dysgenesis. These findings explain the hearing loss observed in some MEIS2 syndrome patients.

#### 4.7.3 Craniofacial Development

Meis2 is essential for cranial neural crest cell function in mandibular arch patterning. Meis2-deficient neural crest cells fail to respond to Sonic hedgehog (Shh) signaling, leading to mandibular hypoplasia and cleft palate. The gene regulatory network of lens induction is also wired through Meis-dependent shadow enhancers of Pax6, explaining the ocular anomalies in some patients.

#### 4.7.4 Restless Legs Syndrome

MEIS2 is associated with restless legs syndrome (RLS), a common neurological disorder. MEIS1 and MEIS2 control distinct processes in human neural stem cells, and their dysregulation contributes to RLS pathogenesis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Insertional Mutagenesis

The MEIS genes were originally discovered through retroviral insertional mutagenesis screens in BXH-2 mice, where proviral integration at the Meis2 locus activated its expression and contributed to myeloid leukemia development. This historical context establishes MEIS2 as a proto-oncogene that can be activated by retroviral elements.

### 5.2 Viral Oncoprotein Interactions

While direct interactions between viral oncoproteins and MEIS2 are not extensively documented, several indirect connections exist:

- **Human papillomavirus (HPV)**: HPV E6/E7 oncoproteins dysregulate cellular transcription factors, and MEIS2 expression is altered in HPV-positive cancers, although direct molecular interactions remain to be established.
- **Epstein-Barr virus (EBV)**: EBV nuclear antigens modulate host gene expression, and MEIS2 has been identified in gene expression signatures of EBV-transformed cells.
- **Hepatitis B virus (HBV)**: HBV X protein (HBx) activates Wnt/β-catenin signaling, and MEIS2C/D isoforms cooperate with this pathway in hepatocellular carcinoma. HBx may synergize with MEIS2 to promote hepatocarcinogenesis.

### 5.3 Bacterial Effectors

MEIS2 has not been directly implicated in bacterial pathogenesis. However, the MEIS2-regulated gene *ITGβ1* (integrin beta 1) is a receptor for multiple bacterial adhesins, suggesting that MEIS2-mediated regulation of integrin expression could influence bacterial invasion.

### 5.4 Immune Evasion Mechanisms

MEIS2 expression in tumor cells may contribute to immune evasion through regulation of antigen presentation and cytokine signaling. In breast cancer, MEIS2 is part of master regulatory networks that control immune-related gene expression. The role of MEIS2 in modulating the tumor immune microenvironment is an active area of investigation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Immunomodulatory Drugs (IMiDs)

MEIS2 is a direct pharmacodynamic target of IMiDs, including lenalidomide, pomalidomide, and thalidomide. These drugs bind to cereblon (CRBN), the substrate receptor of the CRL4-CRBN E3 ubiquitin ligase, and enhance its affinity for MEIS2. This leads to increased ubiquitination and proteasomal degradation of MEIS2, contributing to the anti-myeloma and anti-leukemic activity of IMiDs.

The clinical efficacy of lenalidomide in multiple myeloma is partly attributable to MEIS2 degradation. Patients with high MEIS2 expression may benefit from IMiD-based therapy, while MEIS2 downregulation could confer resistance. Biomarker studies are needed to validate MEIS2 as a predictive marker for IMiD response.

### 6.2 BET Protein Inhibitors

Bromodomain and extra-terminal (BET) protein inhibitors, such as JQ1 and OTX015, modulate MEIS2 expression in multiple myeloma cells. BET inhibitors downregulate MEIS2 transcription by displacing BRD4 from super-enhancers at the MEIS2 locus. Combination therapy with IMiDs and BET inhibitors shows synergistic anti-myeloma activity, providing a rationale for clinical trials.

### 6.3 MEIS Inhibitors

Small-molecule inhibitors targeting MEIS proteins are in preclinical development. Meriç et al. (2023) demonstrated that MEIS inhibitors reduce the viability of primary leukemia cells and leukemia stem cells by inducing apoptosis. These inhibitors disrupt MEIS-PBX interactions or DNA binding, leading to transcriptional dysregulation and cell death. The development of selective MEIS2 inhibitors is ongoing.

### 6.4 Retinoic Acid-Based Therapy

Given the role of retinoic acid in regulating MEIS2 expression, RA-based therapies may be effective in cancers with aberrant MEIS2 activity. All-trans retinoic acid (ATRA) induces differentiation in acute promyelocytic leukemia and may modulate MEIS2 expression in other contexts. However, the effects of RA on MEIS2 are context-dependent, and careful evaluation is required.

### 6.5 Gene Therapy Approaches

For MEIS2 haploinsufficiency syndrome, gene therapy approaches are theoretically possible but face significant challenges. The large size of the MEIS2 coding sequence (~1.4 kb) is amenable to AAV vectors, but the spatiotemporal complexity of MEIS2 expression during development limits the feasibility of postnatal gene replacement. Antisense oligonucleotides (ASOs) targeting splice variants could potentially modulate isoform ratios in diseases where specific isoforms are pathogenic.

### 6.6 Epigenetic Therapies

Given the epigenetic silencing of MEIS2 in prostate, gastric, and colorectal cancers, DNA methyltransferase inhibitors (e.g., 5-azacitidine, decitabine) and histone deacetylase inhibitors (e.g., vorinostat, romidepsin) could restore MEIS2 expression and suppress tumor progression. Clinical trials evaluating these agents in MEIS2-silenced cancers are warranted.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|---|---|---|
| NCBI Gene | 4212 | https://www.ncbi.nlm.nih.gov/gene/4212 |
| Ensembl | ENSG00000134138 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134138 |
| UniProt | O14770 | https://www.uniprot.org/uniprotkb/O14770 |
| RCSB PDB | Multiple (TALE homeodomain structures) | https://www.rcsb.org/ |
| OMIM | 601740 | https://www.omim.org/entry/601740 |
| ClinVar | MEIS2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MEIS2 |
| HGNC | 7000 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7000 |
| GeneCards | MEIS2 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MEIS2 |
| STRING | MEIS2 (O14770) | https://string-db.org/network/O14770 |
| BioGRID | MEIS2 | https://thebiogrid.org/ |
| GTEx | MEIS2 | https://gtexportal.org/home/gene/MEIS2 |
| Human Protein Atlas | MEIS2 | https://www.proteinatlas.org/ENSG00000134138-MEIS2 |
| COSMIC | MEIS2 | https://cancer.sanger.ac.uk/cosmic |
| DECIPHER | MEIS2 | https://www.deciphergenomics.org/ |
| Mouse Genome Informatics | Meis2 | https://www.informatics.jax.org/ |

### Gene Ontology (GO) Terms

| GO Category | Term | Accession |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | Sequence-specific DNA binding | GO:0043565 |
| Molecular Function | Protein heterodimerization activity | GO:0046982 |
| Biological Process | Anterior/posterior pattern specification | GO:0009952 |
| Biological Process | Embryonic forelimb morphogenesis | GO:0035115 |
| Biological Process | Cardiac neural crest cell development | GO:0010002 |
| Biological Process | Inner ear morphogenesis | GO:0042472 |
| Biological Process | Regulation of cell cycle | GO:0051726 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |

---

## 8. Mermaid Diagram: MEIS2 Regulatory Network

```mermaid
flowchart TD
    RA[Retinoic Acid] -->|RAR/RXR| MEIS2[MEIS2 Gene]
    SHH[Sonic Hedgehog] -->|GLI factors| MEIS2
    WNT[Wnt Signaling] -->|β-catenin/TCF| MEIS2
    NFY[NF-Y] -->|CCAAT box| MEIS2
    MIR204[miR-204] -->|mRNA degradation| MEIS2
    MIR2045P[miR-204-5p] -->|translational repression| MEIS2
    IGF2BP2[IGF2BP2] -->|m6A stabilization| MEIS2
    
    MEIS2 -->|Protein| MEIS2

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)